Efficacy and safety of olmesartan medoxomil compared with losartan in patients with hypertension and mild to moderate renal impairment

Trial Profile

Efficacy and safety of olmesartan medoxomil compared with losartan in patients with hypertension and mild to moderate renal impairment

Completed
Phase of Trial: Phase III

Latest Information Update: 13 Oct 2010

At a glance

  • Drugs Olmesartan medoxomil (Primary) ; Losartan
  • Indications Hypertension
  • Focus Therapeutic Use
  • Sponsors Daiichi Sankyo Europe
  • Most Recent Events

    • 05 May 2008 The primary endpoint has been 'Met' (Change in mean sitting dBP, assessed by conventional blood pressure measurements after 12 weeks of treatment), according to the results published in Journal of Clinical Hypertension.
    • 22 Oct 2007 Status changed from in progress to completed.
    • 29 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top